Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A1 | P60842 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Silvestrol SCHEMBL29391620 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL19678561 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| 2'-Episilvestrol SCHEMBL29384144 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL19683897 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL24180257 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL19666161 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL24426807 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL29959484 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL19508495 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A | |
| Silvestrol SCHEMBL18862668 | 1.00 | EIF4A1 (1.00) | EIF4A1CYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137555-A1 | POLYPEPTIDES THAT BIND TO NKP46 | OMNIAB, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2024056619-A1 | 1H-CYCLOPENTA[B]BENZOFURAN DERIVATIVES FOR THE PREVENTION AND TREATMENT OF VIRUS DISEASES | KHR Biotec GmbH (DE) | 2024-03-21 | — | — | WO | disclosed |
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| CN-109476648-B | Sevelamer antibody-drug conjugates and methods of use | 豪夫迈·罗氏有限公司 | 2022-09-13 | — | — | CN | disclosed |
| EP-3464280-B1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2021-10-06 | — | — | EP | disclosed |
| US-20200222545-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-10639378-B2 | Silvestrol antibody-drug conjugates and methods of use | GENENTECH, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| WO-2019177159-A1 | CANCER IMMUNOTHERAPY COMPANION DRUG | 国立大学法人北海道大学 | 2019-09-19 | — | — | WO | disclosed |
| EP-3464280-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2019-04-10 | — | — | EP | disclosed |
| CN-109476648-A | Sevelamer antibody-drug conjugates and methods of use | 豪夫迈·罗氏有限公司 | 2019-03-15 | — | — | CN | disclosed |
| WO-2017214024-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-12-07 | — | — | US | disclosed |
| WO-2006007634-A1 | PROCESSES AND INTERMEDIATES | CERYLID BIOSCIENCES LTD (AU) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | SHBG, EPCAM, ITGAV | EIF4A1 4019/4885CYP3A4 358/4885HIF1A 1718/4885 |
| US-20200222545-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | SHBG, EPCAM, ITGAV | EIF4A1 4019/4885CYP3A4 358/4885HIF1A 1718/4885 |
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | SHBG, EPCAM, ITGAV | EIF4A1 4019/4885CYP3A4 358/4885HIF1A 1718/4885 |
| US-10639378-B2 | Silvestrol antibody-drug conjugates and methods of use | SHBG, EPCAM, ITGAV | EIF4A1 4019/4885CYP3A4 358/4885HIF1A 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.